1. Home
  2. IRWD vs HSTM Comparison

IRWD vs HSTM Comparison

Compare IRWD & HSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.82

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Logo HealthStream Inc.

HSTM

HealthStream Inc.

HOLD

Current Price

$23.08

Market Cap

642.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRWD
HSTM
Founded
1998
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
663.6M
642.6M
IPO Year
2009
1999

Fundamental Metrics

Financial Performance
Metric
IRWD
HSTM
Price
$4.82
$23.08
Analyst Decision
Buy
Hold
Analyst Count
3
1
Target Price
$7.67
$28.00
AVG Volume (30 Days)
1.8M
168.9K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
0.66%
EPS Growth
1400.00
N/A
EPS
0.15
0.61
Revenue
$298,276,000.00
$304,064,000.00
Revenue This Year
$57.95
$9.45
Revenue Next Year
$4.39
$5.12
P/E Ratio
$31.07
$39.59
Revenue Growth
8.88
4.26
52 Week Low
$0.55
$19.50
52 Week High
$5.78
$29.59

Technical Indicators

Market Signals
Indicator
IRWD
HSTM
Relative Strength Index (RSI) 67.86 61.69
Support Level $3.07 $21.19
Resistance Level $5.67 $23.16
Average True Range (ATR) 0.26 0.81
MACD 0.06 0.24
Stochastic Oscillator 94.83 67.61

Price Performance

Historical Comparison
IRWD
HSTM

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

About HSTM HealthStream Inc.

HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.

Share on Social Networks: